BR112023001325A2 - Composto, composição farmacêutica, e, métodos para tratar uma doença causada por um vírus, para inibir a endonuclease dependente de cápsula, para tratar influenza em um mamífero e para prevenir influenza em um mamífero - Google Patents
Composto, composição farmacêutica, e, métodos para tratar uma doença causada por um vírus, para inibir a endonuclease dependente de cápsula, para tratar influenza em um mamífero e para prevenir influenza em um mamíferoInfo
- Publication number
- BR112023001325A2 BR112023001325A2 BR112023001325A BR112023001325A BR112023001325A2 BR 112023001325 A2 BR112023001325 A2 BR 112023001325A2 BR 112023001325 A BR112023001325 A BR 112023001325A BR 112023001325 A BR112023001325 A BR 112023001325A BR 112023001325 A2 BR112023001325 A2 BR 112023001325A2
- Authority
- BR
- Brazil
- Prior art keywords
- mammal
- influenza
- compound
- methods
- pharmaceutical composition
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 7
- 206010022000 influenza Diseases 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 102000004533 Endonucleases Human genes 0.000 title abstract 2
- 108010042407 Endonucleases Proteins 0.000 title abstract 2
- 239000002775 capsule Substances 0.000 title abstract 2
- 230000001419 dependent effect Effects 0.000 title abstract 2
- 241000124008 Mammalia Species 0.000 title 2
- 241000700605 Viruses Species 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063056861P | 2020-07-27 | 2020-07-27 | |
| PCT/US2021/042711 WO2022026285A1 (en) | 2020-07-27 | 2021-07-22 | Polycyclic cap-dependent endonuclease inhibitors for treating or preventing influenza |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023001325A2 true BR112023001325A2 (pt) | 2023-02-14 |
Family
ID=80038102
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023001325A BR112023001325A2 (pt) | 2020-07-27 | 2021-07-22 | Composto, composição farmacêutica, e, métodos para tratar uma doença causada por um vírus, para inibir a endonuclease dependente de cápsula, para tratar influenza em um mamífero e para prevenir influenza em um mamífero |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240018145A1 (https=) |
| EP (1) | EP4188379B1 (https=) |
| JP (1) | JP7695339B2 (https=) |
| KR (1) | KR20230044252A (https=) |
| CN (1) | CN116490190A (https=) |
| AU (1) | AU2021315475A1 (https=) |
| BR (1) | BR112023001325A2 (https=) |
| CA (1) | CA3187516A1 (https=) |
| MX (1) | MX2023001194A (https=) |
| WO (1) | WO2022026285A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118804908A (zh) * | 2022-03-01 | 2024-10-18 | 弗门尼舍有限公司 | 制备γ,δ-不饱和醛衍生物的方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5475109A (en) * | 1994-10-17 | 1995-12-12 | Merck & Co., Inc. | Dioxobutanoic acid derivatives as inhibitors of influenza endonuclease |
| EA200801144A1 (ru) | 2005-10-27 | 2008-10-30 | Сионоги Энд Ко., Лтд. | Полициклическое карбамоилпиридоновое производное, обладающее ингибиторной активностью в отношении интегразы вич |
| MX2013003139A (es) | 2010-09-24 | 2013-06-18 | Shionogi & Co | Profarmaco de derivado de carbamoilpiridona policiclica substituida. |
| TWI695003B (zh) | 2014-12-23 | 2020-06-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
| EP4257137A3 (en) * | 2018-05-31 | 2023-11-01 | Shionogi & Co., Ltd | Polycyclic carbamoylpyridone derivatives for the treatment of hiv |
| AU2019277547B2 (en) | 2018-05-31 | 2024-10-10 | Shionogi & Co., Ltd. | Polycyclic pyridone derivative |
| CN113286793B (zh) | 2018-09-10 | 2024-04-05 | 共结晶制药公司 | 吡咯并吡嗪和吡啶并三嗪类流感病毒复制抑制剂 |
-
2021
- 2021-07-22 KR KR1020237006229A patent/KR20230044252A/ko active Pending
- 2021-07-22 EP EP21848925.0A patent/EP4188379B1/en active Active
- 2021-07-22 CA CA3187516A patent/CA3187516A1/en active Pending
- 2021-07-22 JP JP2023505421A patent/JP7695339B2/ja active Active
- 2021-07-22 CN CN202180065598.0A patent/CN116490190A/zh active Pending
- 2021-07-22 BR BR112023001325A patent/BR112023001325A2/pt unknown
- 2021-07-22 US US18/015,465 patent/US20240018145A1/en active Pending
- 2021-07-22 MX MX2023001194A patent/MX2023001194A/es unknown
- 2021-07-22 AU AU2021315475A patent/AU2021315475A1/en active Pending
- 2021-07-22 WO PCT/US2021/042711 patent/WO2022026285A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CN116490190A (zh) | 2023-07-25 |
| KR20230044252A (ko) | 2023-04-03 |
| EP4188379B1 (en) | 2026-02-25 |
| US20240018145A1 (en) | 2024-01-18 |
| JP7695339B2 (ja) | 2025-06-18 |
| EP4188379A4 (en) | 2024-08-28 |
| MX2023001194A (es) | 2023-04-20 |
| EP4188379A1 (en) | 2023-06-07 |
| CA3187516A1 (en) | 2022-02-03 |
| AU2021315475A1 (en) | 2023-03-02 |
| WO2022026285A1 (en) | 2022-02-03 |
| AU2021315475A8 (en) | 2023-04-06 |
| JP2023535771A (ja) | 2023-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023025358A2 (pt) | Inibidores de protease como antivirais | |
| BR112012006686B8 (pt) | compostos de amida substituída, composições farmacêuticas contendo os ditos compostos, e uso dos mesmos para prevenir e/ou tratar doenças causadas pelo lpa | |
| BR112019000796A2 (pt) | compostos e métodos para tratamento e prevenção da infecção flavivirus | |
| MX2021009246A (es) | Inmunomoduladores, composiciones y metodos de los mismos. | |
| BR112021022758A2 (pt) | Compostos de 1-oxo-isoindolina-5-carboxamida substituídos, suas composições e métodos de tratamento com os mesmos | |
| BR112021020285A2 (pt) | Métodos e composições para degradação de proteína alvejada | |
| BR112022000503A2 (pt) | Compostos úteis para tratar infecções por vírus influenza | |
| CO2019010295A2 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| BR112016028876A2 (pt) | composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos. | |
| BR112012014190A2 (pt) | composição farmacêutica para o tratamento da síndrome do olho seco | |
| CO2019013042A2 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| CO2019010292A2 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| BR112012014899A2 (pt) | composto, composição farmacêutica, método para tratar ou prevenir uma infecção por vírus de hepatite c em um sujeito, método para tratar , prevenir ou melhorar um ou mais sintomas de uma doença hepática ou distúrbio associado a uma infecção por vírus de hepatite c em um sujeito, método para inibir a replicação de um vírus em um hospedeiro, método para inibir a replicação de um vírus | |
| CO2019012035A2 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| BR112015014585A2 (pt) | composto, composição farmacêutica, e, método de tratamento de um ser humano | |
| BR112016020199A8 (pt) | composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso | |
| CL2017001822A1 (es) | Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue | |
| CO2024006727A2 (es) | Compuestos y composiciones macrocíclicos, y métodos para preparar y utilizar los mismos | |
| MX2023006504A (es) | Compuesto de hidroxamato, metodo de preparacion del mismo y aplicacion del mismo. | |
| CL2021002205A1 (es) | Compuesto heterocíclico, composición farmacéutica que lo comprende, método para su preparación, y uso de estos | |
| BR112022006572A2 (pt) | Inibidores orais do fator d do complemento | |
| BR112018008506B8 (pt) | Compostos inibidores do fator xia, composição farmacêutica e usos dos mesmos | |
| BR112018006545A2 (pt) | ?composto, composição farmacêutica, combinação, uso de um composto, e, método para tratamento de uma doença ou condição? | |
| BR112022003768A2 (pt) | Compostos inibidores de perk | |
| BR112021002565A8 (pt) | Composto, sal farmaceuticamente aceitável, tautômero ou estereoisômero do mesmo, composição farmacêutica, processo para a síntese e uso do dito composto |